TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04256317: A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study

Sponsor: Taiho Oncology, Inc. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 316 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$676,368

Rescue Site Savings

+$450,912

Unlock Full NCT04256317 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04256317 Rescue Dossier →